User profiles for Anton I. Rosenbaum
Anton RosenbaumAstraZeneca Verified email at astrazeneca.com Cited by 1455 |
Niemann‐Pick type C disease: molecular mechanisms and potential therapeutic approaches
AI Rosenbaum, FR Maxfield - Journal of neurochemistry, 2011 - Wiley Online Library
… CDs can be delivered via pinocytosis to LE/LY, where they can replace the function of
NPC1 and NPC2 proteins (Rosenbaum et al. 2010b) and promote cholesterol esterification by …
NPC1 and NPC2 proteins (Rosenbaum et al. 2010b) and promote cholesterol esterification by …
Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells
Niemann-Pick type C disease (NPC) is a lysosomal storage disorder causing accumulation
of unesterified cholesterol in lysosomal storage organelles. Recent studies have shown that …
of unesterified cholesterol in lysosomal storage organelles. Recent studies have shown that …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
…, J Dunyak, Y Huang, AI Rosenbaum… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann− Pick type C disease therapeutics
AI Rosenbaum, CC Cosner, CJ Mariani… - Journal of medicinal …, 2010 - ACS Publications
Niemann−Pick type C (NPC) disease is a lysosomal storage disorder characterized at the
cellular level by abnormal accumulation of cholesterol and other lipids in lysosomal storage …
cellular level by abnormal accumulation of cholesterol and other lipids in lysosomal storage …
[HTML][HTML] Bioanalytical methods and strategic perspectives addressing the rising complexity of novel bioconjugates and delivery routes for biotherapeutics
…, JK Meissen, S Mou, M Liang, AI Rosenbaum - BioDrugs, 2022 - Springer
In recent years, an increase in the discovery and development of biotherapeutics employing
new modalities, such as bioconjugates or novel routes of delivery, has created bioanalytical …
new modalities, such as bioconjugates or novel routes of delivery, has created bioanalytical …
[HTML][HTML] ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a unique class of biotherapeutics of inherent
heterogeneity and correspondingly complex absorption, distribution, metabolism, and excretion (…
heterogeneity and correspondingly complex absorption, distribution, metabolism, and excretion (…
[HTML][HTML] Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
…, C Patel, L Liang, L Tseng, Y Huang, AI Rosenbaum… - Scientific reports, 2021 - nature.com
Peptide therapeutics are increasingly used in the treatment of disease, but their administration
by injection reduces patient compliance and convenience, especially for chronic diseases…
by injection reduces patient compliance and convenience, especially for chronic diseases…
First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody–drug conjugate MEDI4276 in patients with HER2-positive advanced breast or …
…, AR Tan, AM Storniolo, K Balic, AI Rosenbaum… - Molecular Cancer …, 2021 - AACR
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in
subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-…
subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-…
Design and preclinical evaluation of a novel B7-H4–directed antibody–drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor …
…, M Davies, A Lewis, Y Huang, AI Rosenbaum… - Clinical Cancer …, 2023 - AACR
Purpose: We evaluated the activity of AZD8205, a B7-H4–directed antibody–drug conjugate
(ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination …
(ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination …
AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
…, LI Cheng, J Dunyak, Y Huang, AI Rosenbaum… - Medrxiv, 2021 - medrxiv.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (…
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (…